Why did Medplus Health Services (MEDPLUS) stock move recently?

On 8/4/2026, Medplus Health Services moved -4.3% — No specific catalyst identified for the 4.3% drop on August 4; the stock has been under pressure following weak Q1 results and analyst target cuts in late July, with a sell rating noted on August 1. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Medplus Health Services (MEDPLUS) overvalued or fairly valued?

MarketChacha shows Medplus Health Services's valuation in context — a forward P/E of about 29.2, a price-to-book of about 4.0 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Medplus Health Services's revenue?

Medplus Health Services reported revenue of ₹6,892 Cr for FY2026, with net profit of ₹220 Cr, per official filings.

What is the share price of Medplus Health Services (MEDPLUS)?

Medplus Health Services last traded at ₹676.35 (+2.5% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Medplus Health Services

MEDPLUS · NSE · Healthcare · India

Snapshot

TickerMEDPLUS

ExchangeNSE

SectorHealthcare

IndustryPharmaceutical Retailers

CountryIndia

Employees28,872

HeadquartersHyderabad, India

Websitewww.medplusindia.com

Filings tracked15

About Medplus Health Services

MedPlus Health Services Limited engages in the retail trading of medicines and general items in India. It manufactures and trades in pharmaceutical and wellness items, such as prescription medicines, over-the-counter drugs, vitamins, vitamins, medical devices, and diagnostic test kits; and fast-moving consumer goods (FMCG), including personal and home care products like toiletries, baby care items, soaps, detergents, and sanitizers. The company also engages in wholesale cash and carry; provision of diagnostic, pathological, and laboratory testing services, as well as contract manufacturing of private-label pharmaceuticals, wellness products, and FMCG goods; and operates diagnostic centres. It distributes its products through retail and online channels. The company was incorporated in 2006 and is based in Hyderabad, India.

Who owns it

Promoters30.1%
Institutions40.7%
Public & other29.1%

55 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend1.1% → 3.2%

Margin has expanded by about 2.1 points — the business is getting more profitable.

Growth qualityrev 15% · PAT 64%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next fiscal year

Rev ₹9,211 Cr · EPS 22.68

Est. earnings growth +36.7%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 4

Revenue (FY2026)

₹6,892 Cr

Net margin

3.2%

Revenue CAGR (3y)

+14.8%

Profit CAGR (3y)

+64.0%

Net profit (FY2026)

₹220 Cr

Ask MarketChacha about MEDPLUS

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Aug 4, 2026
No specific catalyst identified for the 4.3% drop on August 4; the stock has been under pressure following weak Q1 results and analyst target cuts in late July, with a sell rating noted on August 1.
source 1 ↗source 2 ↗· confidence: low
Jul 23, 2026
Medplus rebounded ~3.4% after plunging 13-18% the prior day on weak Q1 FY27 results (profit down ~21-22% YoY) that triggered a 52-week low; no new positive catalyst reported for July 23.
source 1 ↗source 2 ↗· confidence: medium

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹6,892 Cr	₹220 Cr	3.2%
FY2025	₹6,136 Cr	₹150 Cr	2.4%
FY2024	₹5,625 Cr	₹65 Cr	1.2%
FY2023	₹4,558 Cr	₹50 Cr	1.1%

Quarterly

Period	Revenue	Net profit	Net margin
Q1 FY27	₹1,880 Cr	₹33 Cr	1.8%
Q4 FY26	₹1,864 Cr	₹64 Cr	3.4%
Q3 FY26	₹1,806 Cr	₹58 Cr	3.2%
Q2 FY26	₹1,679 Cr	₹56 Cr	3.3%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

Filings & announcements

2026

Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
BSE8/21/2026
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Submission of Voting results Along with Scrutinizer''s Report of the 20th Annual General Meeting of the company.
BSE8/18/2026material
Shareholder Meeting / Postal Ballot-Outcome of AGM
Summary Proceedings of 20th Annual General Meeting of the Company held on August 17, 2026
BSE8/17/2026material
Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
BSE7/31/2026
Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
BSE7/24/2026
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for ICICI Prudential Mutual Fund
BSE7/24/2026
Business Responsibility and Sustainability Reporting (BRSR)
BRSR for F.Y. 2025-26
BSE7/23/2026
Notice Of 20Th Annual General Meeting Of The Company For The Financial Year 2025-26
Notice of 20th AGM of the Company for the F.Y.2025-26
BSE7/23/2026material
Reg. 34 (1) Annual Report.
20th Annual Report of the Company for the Financial Year 2025-26 along with Notice to the Shareholders for Annual General Meeting
BSE7/23/2026
Request To Ignore Inadvertent Filing Of Investor Presentation
Request to Ignore Inadvertent Filing of Investor Presentation
BSE7/22/2026
Request To Ignore Inadvertent Filing Of Investor Presentation
Request to ignore Inadvertent Filing of Investor Presentation.
BSE7/22/2026
Request To Ignore Inadvertent Filing Of Investor Presentation
Request to Ignore Inadvertent Filing of Investor Presentation.
BSE7/22/2026
Request To Ignore Inadvertent Filing Of Investor Presentation
Request to Ignore Inadvertent Filing of Investor Presentation
BSE7/22/2026
Request To Ignore Inadvertent Filing Of Investor Presentation
Request to Ignore Inadvertent Filing of Investor Presentation
BSE7/22/2026
Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
BSE7/22/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.